
Apple COO Williams to transition role to Sabih Khan later this month
Don't Miss TipRanks' Half-Year Sale

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Insider
38 minutes ago
- Business Insider
APA (APA) Receives a Rating Update from a Top Analyst
Roth MKM analyst Leo Mariani maintained a Buy rating on APA today and set a price target of $24.00. The company's shares closed today at $20.45. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Mariani covers the Energy sector, focusing on stocks such as EOG Resources, Diamondback, and Matador Resources. According to TipRanks, Mariani has an average return of 27.8% and a 62.86% success rate on recommended stocks. APA has an analyst consensus of Hold, with a price target consensus of $20.94. APA market cap is currently $7B and has a P/E ratio of 7.02.


Business Insider
38 minutes ago
- Business Insider
REV Group management to meet with DA Davidson
Meeting to be held in New York on July 15 hosted by DA Davidson. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.


Business Insider
an hour ago
- Business Insider
Candel Therapeutics initiated with a Buy at Brookline
Brookline analyst Kemp Dolliver initiated coverage of Candel Therapeutics (CADL) with a Buy rating and $25 price target Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies, the analyst tells investors in a research note. The firm says the company's lead candidate CAN-2409 met the primary endpoint in a Phase 3 trial in newly-diagnosed localized prostate cancer in intermediate- or high-risk patients, setting the stage for an application filing in Q4 of 2026. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.